Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 10—October 2007
Dispatch

Ciprofloxacin-Resistant Neisseria meningitidis, Delhi, India

Smita Singhal*, Kedar P. Purnapatre*, Vandana Kalia*, Smita Dube*, Deepti Nair†, Monorama Deb†, Pushpa Aggarwal‡, Sunil Gupta§, Dilip J. Upadhyay*, Awdhesh Kalia¶, and V. Samuel Raj*Comments to Author 
Author affiliations: *Ranbaxy Research Laboratories, Gurgaon, India; †Vardhman Mahaveer Medical College and Safdarjung Hospital, New Delhi, India; ‡Ministry of Health and Family Welfare, New Delhi, India; §National Institute of Communicable Diseases, Delhi, India; ¶Caribbean Epidemiology Centre, Port of Spain, Trinidad and Tobago;

Main Article

Table

Antimicrobial susceptibility pattern of Neisseria meningitidis isolates from the recurrent outbreak during January– March 2006, Delhi, India*

Isolate MIC (μg/mL)
PEN CRO RIF CIP GAT MXF LVX SPX NOR NAL
SFDJ M-1 0.125 0.008 0.004 0.125 0.03 0.125 0.125 0.06 0.125 >16
SFDJ M-2 0.125 0.008 0.004 0.25 0. 25 0.125 0.03 0.06 0.25 >16
SFDJ 691 0.03 <0.001 0.125 0.25 0.25 0.5 0.25 0.25 0.5 >16
SFDJ 306 0.03 0.008 0.008 0.125 0.06 0.125 0.25 0.06 0.25 >16
SFDJ 651 0.06 0.002 0.03 0. 5 0.125 0.25 0.25 0.125 0.5 >16
SFDJ 568 0.125 0.002 0.06 0.25 0.125 0.25 0.25 0.125 0.5 >16
SFDJ 668 0.06 0.002 0.06 0.25 0.125 0.25 0.125 0.125 0.25 >16
SFDJ 270 0.125 0.008 0.015 0.125 0.06 0.125 0.125 0.125 0.25 >16
SFDJ MA-3 0.06 0.004 0.125 0.5 0.25 0.25 1 1 1 >16
SFDJ 339 0.125 <0.001 0.25 0.25 0.25 0.25 0.25 0.25 0.25 >16
SFDJ 58 0.125 0.008 0.004 0.125 0.06 0.125 0.03 0.06 0.25 >16

*PEN, penicillin; CRO, ceftriaxone; RIF, rifampin; CIP, ciprofloxacin; GAT, gatifloxacin; MFX, moxifloxacin; LVX, levofloxacin; SPX, sparfloxacin; NOR, norfloxacin; NAL, nalidixic acid.

Main Article

Page created: July 02, 2010
Page updated: July 02, 2010
Page reviewed: July 02, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external